Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men
Ioanna Gouni-Berthold,
Heiner K. Berthold,
John P. Chamberland,
Wilhelm Krone,
Christos S. Mantzoros,
Ioanna Gouni-Berthold
Department of Internal Medicine II, University of Cologne, Cologne, Germany,
Search for more papers by this authorHeiner K. Berthold
Medical Faculty of the University of Bonn, Bonn, Germany and
Search for more papers by this authorJohn P. Chamberland
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorWilhelm Krone
Department of Internal Medicine II, University of Cologne, Cologne, Germany,
Search for more papers by this authorChristos S. Mantzoros
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorIoanna Gouni-Berthold,
Heiner K. Berthold,
John P. Chamberland,
Wilhelm Krone,
Christos S. Mantzoros,
Ioanna Gouni-Berthold
Department of Internal Medicine II, University of Cologne, Cologne, Germany,
Search for more papers by this authorHeiner K. Berthold
Medical Faculty of the University of Bonn, Bonn, Germany and
Search for more papers by this authorJohn P. Chamberland
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorWilhelm Krone
Department of Internal Medicine II, University of Cologne, Cologne, Germany,
Search for more papers by this authorChristos S. Mantzoros
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Search for more papers by this author Christos S. Mantzoros, Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, ST816, Boston, MA 02215, USA. Tel.: +1-617-667-8630; Fax: +1-617-667-8634; E-mail: [email protected]
Summary
Objective Statin therapy decreases cardiovascular morbidity and mortality, and ezetimibe, a novel cholesterol absorption inhibitor has both lipid-lowering and anti-atherosclerotic effects in animal models. As several adipokines, that is, adiponectin, high molecular weight (HMW) adiponectin, leptin and/or possibly resistin are involved in the pathogenesis of insulin resistance (IR), dyslipidaemia and atherosclerosis, we investigated whether ezetimibe and/or statin treatment may modulate serum concentrations of these four major adipokines.
Research design and methods One-centre, randomized, parallel three-group study in 72 healthy men [mean age 32 ± 9 years, mean body mass index (BMI) 25·7 ± 3·2 kg/m2].
Patients Seventy-two healthy men. Each group of 24 subjects received a 14-day treatment with either ezetimibe (10 mg/day), simvastatin (40 mg/day) or their combination. Blood was drawn before and after the 14-day treatment period.
Measurements Lipid levels, IR indices, serum leptin, adiponectin, HMW adiponectin and resistin concentrations.
Results Neither ezetimibe nor simvastatin or their combination had any effect on serum leptin, adiponectin, HMW adiponectin and resistin concentrations. Baseline leptin levels correlated positively, while adiponectin and HMW adiponectin negatively, with BMI. Leptin concentrations correlated negatively while adiponectin and HMW adiponectin positively with plasma high-density lipoprotein-cholesterol concentrations. Resistin concentrations were not associated with BMI, lipid levels or indicators of IR.
Conclusions Treatment with ezetimibe, simvastatin or their combination does not alter circulating levels of adiponectin, leptin or resistin in adult healthy men.
References
- 1 LaRosa, J.C., He, J. & Vupputuri, S. (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Journal of the American Medical Association, 282, 2340–2346.
- 2 Liao, J.K. (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. American Journal of Cardiology, 96, 24F–33F.
- 3 Davis, H.R. Jr, Compton, D.S., Hoos, L. & Tetzloff, G. (2001) Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 2032–2038.
- 4 Sethi, J.K. & Vidal-Puig, A.J. (2007) Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. Journal of Lipid Research, 48, 1253–1262.
- 5 Han, S.H., Quon, M.J., Kim, J.A. & Koh, K.K. (2007) Adiponectin and cardiovascular disease: response to therapeutic interventions. Journal of the American College of Cardiology, 49, 531–538.
- 6 Kadowaki, T. & Yamauchi, T. (2005) Adiponectin and adiponectin receptors. Endocrine Reviews, 26, 439–451.
- 7 McTernan, P.G., Kusminski, C.M. & Kumar, S. (2006) Resistin. Current Opinions in Lipidology, 17, 170–175.
- 8 Chu, C.S., Lee, K.T., Lee, M.Y., Su, H.M., Voon, W.C., Sheu, S.H. & Lai, W.T. (2006) Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiologica, 61, 263–269.
- 9 Gannage-Yared, M.H., Azar, R.R., Mm-Azar, M., Khalife, S., Germanos-Haddad, M., Neemtallah, R. & Halaby, G. (2005) Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism, 54, 947–951.
- 10 Koh, K.K., Quon, M.J., Han, S.H., Chung, W.J., Ahn, J.Y., Seo, Y.H., Choi, I.S. & Shin, E.K. (2005) Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. Journal of the American College of Cardiology, 45, 1649–1653.
- 11 Koh, K.K., Quon, M.J., Han, S.H., Ahn, J.Y., Jin, D.K., Kim, H.S., Kim, D.S. & Shin, E.K. (2005) Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension, 45, 1088–1093.
- 12 Shetty, G.K., Economides, P.A., Horton, E.S., Mantzoros, C.S. & Veves, A. (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 27, 2450–2457.
- 13 Von, E.M., Schneider, J.G., Hadziselimovic, S., Hamann, A., Bierhaus, A., Nawroth, P.P. & Dugi, K.A. (2005) Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care, 28, 754–755.
- 14 Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412–419.
- 15 Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follmann, D.A., Sullivan, G. & Quon, M.J. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism, 85, 2402–2410.
- 16 McAuley, K.A., Williams, S.M., Mann, J.I., Walker, R.J., Lewis-Barned, N.J., Temple, L.A. & Duncan, A.W. (2001) Diagnosing insulin resistance in the general population. Diabetes Care, 24, 460–464.
- 17 Mantzoros, C.S., Li, T., Manson, J.E., Meigs, J.B. & Hu, F.B. (2005) Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 90, 4542–4548.
- 18 Bluher, M., Brennan, A.M., Kelesidis, T., Kratzsch, J., Fasshauer, M., Kralisch, S., Williams, C.J. & Mantzoros, C.S. (2007) Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care, 30, 280–285.
- 19 Kantartzis, K., Fritsche, A., Tschritter, O., Thamer, C., Haap, M., Schafer, S., Stumvoll, M., Haring, H.U. & Stefan, N. (2005) The association between plasma adiponectin and insulin sensitivity in humans depends on obesity. Obesity Research, 13, 1683–1691.
- 20 Westphal, S., Borucki, K., Taneva, E., Makarova, R. & Luley, C. (2006) Adipokines and treatment with niacin. Metabolism, 55, 1283–1285.
- 21 Yin, W.H., Jen, H.L., Chen, J.W., Lin, S.J. & Young, M.S. (2006) Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metabolism, 32, 229–235.
- 22 Fajas, L., Schoonjans, K., Gelman, L., Kim, J.B., Najib, J., Martin, G., Fruchart, J.C., Briggs, M., Spiegelman, B.M. & Auwerx, J. (1999) Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Molecular Cell Biology, 19, 5495–5503.
- 23 Landrier, J.F., Thomas, C., Grober, J., Duez, H., Percevault, F., Souidi, M., Linard, C., Staels, B. & Besnard, P. (2004) Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-α-dependent. Journal of Biological Chemistry, 279, 45512–45518.
- 24 Martin, G., Duez, H., Blanquart, C., Berezowski, V., Poulain, P., Fruchart, J.C., Najib-Fruchart, J., Glineur, C. & Staels, B. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. Journal of Clinical Investigations, 107, 1423–1432.
- 25 Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K., Motoshima, H., Taguchi, T., Sonoda, K., Kukidome, D., Takuwa, Y., Kawada, T., Brownlee, M., Nishikawa, T. & Araki, E. (2007) Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circulation Research, 100, 1442–1451.
- 26 Iwaki, M., Matsuda, M., Maeda, N., Funahashi, T., Matsuzawa, Y., Makishima, M. & Shimomura, I. (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52, 1655–1663.
- 27 During, A., Dawson, H.D. & Harrison, E.H. (2005) Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. Journal of Nutrition, 135, 2305–2312.
- 28 Telford, D.E., Sutherland, B.G., Edwards, J.Y., Andrews, J.D., Barrett, P.H. & Huff, M.W. (2007) The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. Journal of Lipid Research, 48, 699–708.
- 29 Seo, J.B., Moon, H.M., Noh, M.J., Lee, Y.S., Jeong, H.W., Yoo, E.J., Kim, W.S., Park, J., Youn, B.S., Kim, J.W., Park, S.D. & Kim, J.B. (2004) Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. Journal of Biological Chemistry, 279, 22108–22117.
- 30 Brennan, A.M. & Mantzoros, C.S. (2006) Drug insight: the role of leptin in human physiology and pathophysiology – emerging clinical applications. Nature Clinical Practice Endocrinological Metabolism, 2, 318–327.
- 31 Brennan, A.M., Li, T.Y., Kelesidis, I., Gavrila, A., Hu, F.B. & Mantzoros, C.S. (2007) Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study. Diabetologia, 50, 1178–1185.
- 32 Pantsulaia, I., Livshits, G., Trofimov, S. & Kobyliansky, E. (2007) Genetic and environmental determinants of circulating resistin level in a community-based sample. European Journal of Endocrinology, 156, 129–135.
- 33 Van, H.M., Austin, T.M., Farley, C., Cook, J.A., Tetzloff, G.G. & Davis, H.R. (2001) Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes, 50, 1330–1335.
- 34 Reilly, M.P., Lehrke, M., Wolfe, M.L., Rohatgi, A., Lazar, M.A. & Rader, D.J. (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 111, 932–939.
- 35 Jurimae, J. & Jurimae, T. (2007) Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. American Journal of Physiological and Endocrinological Metabolism, 293, E42–E47.
- 36 Magni, P., Liuzzi, A., Ruscica, M., Dozio, E., Ferrario, S., Bussi, I., Minocci, A., Castagna, A., Motta, M. & Savia, G. (2005) Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clinical Endocrinology, 62, 189–196.
- 37 Snijder, M.B., Heine, R.J., Seidell, J.C., Bouter, L.M., Stehouwer, C.D., Nijpels, G., Funahashi, T., Matsuzawa, Y., Shimomura, I. & Dekker, J.M. (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care, 29, 2498–2503.
- 38 Okada, T., Saito, E., Kuromori, Y., Miyashita, M., Iwata, F., Hara, M. & Harada, K. (2006) Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children. Atherosclerosis, 188, 179–183.
- 39 Bansal, N., Charlton-Menys, V., Pemberton, P., McElduff, P., Oldroyd, J., Vyas, A., Koudsi, A., Clayton, P.E., Cruickshank, J.K. & Durrington, P.N. (2006) Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity. Journal of Clinical Endocrinology and Metabolism, 91, 2244–2249.
- 40 Hirose, H., Saito, I., Kawai, T., Tsujioka, M., Kawabe, H. & Saruta, T. (2001) Relationships between baseline serum leptin levels and 2-year changes in body mass index, blood pressure and metabolic parameters in Japanese male adolescents and middle-aged men. Clinical Science, 100, 145–150.
- 41 Wannamethee, S.G., Tchernova, J., Whincup, P., Lowe, G.D., Kelly, A., Rumley, A., Wallace, A.M. & Sattar, N. (2007) Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis, 191, 418–426.
- 42 Heilbronn, L.K., Rood, J., Janderova, L., Albu, J.B., Kelley, D.E., Ravussin, E. & Smith, S.R. (2004) Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. Journal of Clinical Endocrinology and Metabolism, 89, 1844–1848.
- 43 Gavrila, A., Chan, J.L., Yiannakouris, N., Kontogianni, M., Miller, L.C., Orlova, C. & Mantzoros, C.S. (2003) Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. Journal of Clinical Endocrinology and Metabolism, 88, 4823–4831.
- 44 Silha, J.V., Krsek, M., Skrha, J.V., Sucharda, P., Nyomba, B.L. & Murphy, L.J. (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. European Journal of Endocrinology, 149, 331–335.
- 45 Heliovaara, M.K., Strandberg, T.E., Karonen, S.L. & Ebeling, P. (2006) Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Hormone Metabolism Research, 38, 336–340.
Citing Literature
